

Robert A Stockley

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8964926/robert-a-stockley-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

8,123
citations

36
h-index

89
g-index

117
ext. papers

9,864
ext. citations

6.5
avg, IF

6.05
L-index

#	Paper	IF	Citations
110	Case-finding and improving patient outcomes for chronic obstructive pulmonary disease in primary care: the BLISS research programme including cluster RCT. <i>Programme Grants for Applied Research</i> , 2021 , 9, 1-148	1.5	
109	Small Airways Response to Bronchodilators in Adults with Asthma or COPD: A Systematic Review. <i>International Journal of COPD</i> , 2021 , 16, 3065-3082	3	0
108	Relationship between Depression and Anxiety, Health Status and Lung Function in Patients with Alpha-1 Antitrypsin Deficiency. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021 , 1-9	2	
107	There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements. <i>International Journal of COPD</i> , 2021 , 16, 835-840	3	3
106	Catching "Early" COPD - The Diagnostic Conundrum. <i>International Journal of COPD</i> , 2021 , 16, 957-968	3	0
105	Reply to Thomson, to Neder ., and to Wouters. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 112	10.2	
104	From GOLD 0 to Pre-COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 414-423	10.2	26
103	Development and Relevance of Hypercapnia in COPD. <i>Canadian Respiratory Journal</i> , 2021 , 2021, 6623093	3.1	1
102	Relationship of CT densitometry to lung physiological parameters and health status in alpha-1 antitrypsin deficiency: initial report of a centralised database of the NIHR rare diseases translational research collaborative. <i>BMJ Open</i> , 2020 , 10, e036045	3	2
101	Alpha-1 Antitrypsin Deficiency: Have We Got the Right Proteinase?. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020 , 7, 163-171	2.7	2
100	An overview of exacerbations of chronic obstructive pulmonary disease: Can tests of small airwaysR function guide diagnosis and management?. <i>Annals of Thoracic Medicine</i> , 2020 , 15, 54-63	2.2	3
99	Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency. <i>International Journal of COPD</i> , 2020 , 15, 3313-3322	3	3
98	Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency. <i>International Journal of COPD</i> , 2020 , 15, 3183-3192	3	2
97	Protocol for the EARCO Registry: a pan-European observational study in patients with Antitrypsin deficiency. <i>ERJ Open Research</i> , 2020 , 6,	3.5	4
96	Clinical considerations in individuals with Antitrypsin PI*SZ genotype. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	14
95	Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease?. <i>Drugs and Aging</i> , 2019 , 36, 823-840	4.7	4
94	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	722

93	The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 318-326	10.2	42
92	Neutrophil phenotypes in chronic lung disease. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 951-967	3.8	15
91	Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary care. <i>Thorax</i> , 2019 , 74, 730-739	7.3	7
90	α ₁ -antitrypsin deficiency 2019 , 744-747		
89	A specific proteinase 3 activity footprint in α ₁ -antitrypsin deficiency. <i>ERJ Open Research</i> , 2019 , 5,	3.5	9
88	Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 1195-1204	10.2	49
87	Health status decline in α ₁ antitrypsin deficiency: a feasible outcome for disease modifying therapies?. <i>Respiratory Research</i> , 2018 , 19, 137	7.3	10
86	Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases. <i>Respiratory Research</i> , 2018 , 19, 180	7.3	24
85	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Respirology</i> , 2017 , 22, 575-601	3.6	228
84	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	398
83	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 557-582	10.2	1682
82	The Use of Plasmapheresis in Patients with Bronchiectasis with <i>Pseudomonas aeruginosa</i> Infection and Inhibitory Antibodies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 955-958	10.2	8
81	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , 2017 , 53, 128-149	0.7	247
80	Maximal mid-expiratory flow detects early lung disease in α ₁ -antitrypsin deficiency. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	26
79	Is periodontitis a comorbidity of COPD or can associations be explained by shared risk factors/behaviors?. <i>International Journal of COPD</i> , 2017 , 12, 1339-1349	3	56
78	Post Hoc: Two (or More) for the Price of One. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 844-846	10.2	
77	Patterns and characterization of COPD exacerbations using real-time data collection. <i>International Journal of COPD</i> , 2017 , 12, 427-434	3	7
76	European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α ₁ -antitrypsin deficiency. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	149

75	Small airways disease: time for a revisit?. <i>International Journal of COPD</i> , 2017 , 12, 2343-2353	3	29
74	Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 720-730	35.1	42
73	Pulmonary Physiology of Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, and Alpha-1 Antitrypsin Deficiency. <i>Annals of the American Thoracic Society</i> , 2016 , 13 Suppl 2, S118-22	4.7	3
72	Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?. <i>International Journal of COPD</i> , 2016 , 11, 1745-56	3	26
71	COPD service delivery in the UK. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 426-8	35.1	1
70	α 1-antitrypsin: a polyfunctional protein?. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 341-3	35.1	9
69	α 1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015 , 308, L179-90	5.8	41
68	Relationship between Change in Lung Density and Long-Term Progression of Lung Function. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 114-6	10.2	12
67	The Relationship of the Fibrinogen Cleavage Biomarker A α Val360 With Disease Severity and Activity in α 1-Antitrypsin Deficiency. <i>Chest</i> , 2015 , 148, 382-388	5.3	20
66	Antitrypsin Deficiency Assessment and Programme for Treatment (ADAPT): The United Kingdom Registry. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015 , 12 Suppl 1, 63-8	2	15
65	The multiple facets of alpha-1-antitrypsin. <i>Annals of Translational Medicine</i> , 2015 , 3, 130	3.2	19
64	α 1-Antitrypsin deficiency: clinical variability, assessment, and treatment. <i>Trends in Molecular Medicine</i> , 2014 , 20, 105-15	11.5	61
63	Alpha1-antitrypsin review. <i>Clinics in Chest Medicine</i> , 2014 , 35, 39-50	5.3	58
62	Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. <i>Blood</i> , 2014 , 123, 239-48	2.2	205
61	Spirometric and gas transfer discordance in a α 1-antitrypsin deficiency. patient characteristics and progression. <i>Chest</i> , 2014 , 145, 1316-1324	5.3	13
60	Biomarkers in chronic obstructive pulmonary disease: confusing or useful?. <i>International Journal of COPD</i> , 2014 , 9, 163-77	3	29
59	Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014 , 1, 166-184	2.7	19
58	TargetCOPD: a pragmatic randomised controlled trial of targeted case finding for COPD versus routine practice in primary care: protocol. <i>BMC Pulmonary Medicine</i> , 2014 , 14, 157	3.5	14

57	Progranulin is a substrate for neutrophil-elastase and proteinase-3 in the airway and its concentration correlates with mediators of airway inflammation in COPD. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014 , 306, L80-7	5.8	27
56	Bronchiectasis in older patients with chronic obstructive pulmonary disease : prevalence, diagnosis and therapeutic management. <i>Drugs and Aging</i> , 2013 , 30, 215-25	4.7	6
55	Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. <i>Respiratory Medicine</i> , 2013 , 107, 524-33	4.6	108
54	Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. <i>Orphanet Journal of Rare Diseases</i> , 2013 , 8, 149	4.2	53
53	Age related development of respiratory abnormalities in non-index α 1 antitrypsin deficient studies. <i>Respiratory Medicine</i> , 2013 , 107, 387-93	4.6	21
52	The link between chronic periodontitis and COPD: a common role for the neutrophil?. <i>BMC Medicine</i> , 2013 , 11, 241	11.4	35
51	Recent advances in α 1-antitrypsin deficiency-related lung disease. <i>Expert Review of Respiratory Medicine</i> , 2013 , 7, 213-29; quiz 230	3.8	34
50	AEVal360: a marker of neutrophil elastase and COPD disease activity. <i>European Respiratory Journal</i> , 2013 , 41, 31-8	13.6	41
49	α 1-antitrypsin deficiency: what has it ever done for us?. <i>Chest</i> , 2013 , 144, 1923-1929	5.3	8
48	Global Initiative for Chronic Obstructive Lung Disease 2011 symptom/risk assessment in α 1-antitrypsin deficiency. <i>Chest</i> , 2013 , 144, 1152-1162	5.3	15
47	A novel model and molecular therapy for Z alpha-1 antitrypsin deficiency. <i>Mammalian Genome</i> , 2012 , 23, 241-9	3.2	9
46	Randomised controlled trial for emphysema with a selective agonist of the β type retinoic acid receptor. <i>European Respiratory Journal</i> , 2012 , 40, 306-12	13.6	70
45	Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 1125-32	10.2	53
44	Variability of sputum inflammatory mediators in COPD and α 1-antitrypsin deficiency. <i>European Respiratory Journal</i> , 2012 , 40, 561-9	13.6	33
43	Eureka?. <i>Radiology</i> , 2011 , 259, 610-1; author reply 611-2	20.5	
42	Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 1176-86	10.2	111
41	The fibrinogen cleavage product AEVal360, a specific marker of neutrophil elastase activity in vivo. <i>Thorax</i> , 2011 , 66, 686-91	7.3	42
40	Outdoor air pollution is associated with rapid decline of lung function in alpha-1-antitrypsin deficiency. <i>Occupational and Environmental Medicine</i> , 2010 , 67, 556-61	2.1	30

39	Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessments. <i>Therapeutic Advances in Respiratory Disease</i> , 2010 , 4, 319-32	4.9	29
38	Tumor necrosis factor- α rs361525 polymorphism is associated with increased local production and downstream inflammation in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 192-9	10.2	38
37	Therapeutic efficacy of α 1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. <i>Respiratory Research</i> , 2010 , 11, 136	7.3	132
36	Emerging drugs for alpha-1-antitrypsin deficiency. <i>Expert Opinion on Emerging Drugs</i> , 2010 , 15, 685-94	3.7	9
35	Studies of gamma-glutamyl transferase in alpha-1 antitrypsin deficiency. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2010 , 7, 126-32	2	16
34	CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency. <i>Chest</i> , 2009 , 136, 1284-1290	5.3	36
33	Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009 , 6, 177-84	2	137
32	Mortality in alpha-1-antitrypsin deficiency in the United Kingdom. <i>Respiratory Medicine</i> , 2009 , 103, 1540-7	4.6	25
31	Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency. <i>Respiratory Research</i> , 2009 , 10, 75	7.3	63
30	The Neutrophil and Its Special Role in Chronic Obstructive Pulmonary Disease		2
29	Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. <i>Current Medical Research and Opinion</i> , 2009 , 25, 1235-45	2.5	51
28	Phenotypic differences in alpha 1 antitrypsin-deficient sibling pairs may relate to genetic variation. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2008 , 5, 353-9	2	26
27	Reported and unreported exacerbations of COPD: analysis by diary cards. <i>Chest</i> , 2008 , 133, 34-41	5.3	65
26	The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 19-26	10.2	636
25	Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 1215-21	10.2	170
24	Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from alpha1-antitrypsin deficiency. <i>Chest</i> , 2007 , 132, 909-15	5.3	50
23	Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. <i>Respiratory Research</i> , 2006 , 7, 147	7.3	34
22	Alpha-1-antitrypsin replacement therapy: current status. <i>Current Opinion in Pulmonary Medicine</i> , 2006 , 12, 125-31	3	31

21	Exacerbations of COPD diagnosed in primary care: changes in spirometry and relationship to symptoms. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005 , 2, 419-25	2	9
20	Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 170, 1172-8	10.2	177
19	Proteinases in COPD 2004 , 75-99		1
18	The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002 , 165, 1494-8	10.2	130
17	Neutrophils and the pathogenesis of COPD. <i>Chest</i> , 2002 , 121, 151S-155S	5.3	207
16	The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in alpha(1)-antitrypsin deficiency (PiZ). <i>Chest</i> , 2002 , 122, 1247-55	5.3	31
15	Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. <i>Chest</i> , 2000 , 117, 1638-45	5.3	338
14	Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. <i>American Journal of Medicine</i> , 2000 , 109, 288-95	2.4	317
13	Role of inflammation in respiratory tract infections. <i>American Journal of Medicine</i> , 1995 , 99, 8S-13S	2.4	40
12	1 alpha,25-Dihydroxyvitamin D3 promotes monocytopoiesis and suppresses granulocytopoiesis in cultures of normal human myeloid blast cells. <i>Journal of Leukocyte Biology</i> , 1994 , 56, 124-32	6.5	14
11	Monocyte adherence to fibronectin: role of CD11/CD18 integrins and relationship to other monocyte functions. <i>Journal of Leukocyte Biology</i> , 1992 , 51, 400-8	6.5	31
10	Extracellular proteolysis of fibronectin by neutrophils: characterization and the effects of recombinant cytokines. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1991 , 4, 330-7	5.7	22
9	Effects of neutrophil adherence on the characteristics of receptors for tumor necrosis factor-alpha. <i>FEBS Letters</i> , 1991 , 282, 373-6	3.8	2
8	Effects of plasma, tumour necrosis factor, endotoxin and dexamethasone on extracellular proteolysis by neutrophils from healthy subjects and patients with emphysema. <i>Clinical Science</i> , 1989 , 77, 35-41	6.5	19
7	Biliary beta 2-microglobulin in liver allograft rejection. <i>Hepatology</i> , 1988 , 8, 1565-70	11.2	21
6	The assessment of alpha 1 proteinase inhibitor form and function in lung lavage fluid from healthy subjects. <i>Biological Chemistry Hoppe-Seyler</i> , 1988 , 369, 1065-74		17
5	Evidence for lipid-associated serine proteases and metalloproteases in human bronchoalveolar lavage fluid. <i>Clinical Science</i> , 1988 , 75, 601-7	6.5	17
4	Determination of elastase inhibitory activity of alpha 1-proteinase inhibitor and bronchial antileukoprotease: different results using insoluble elastin or synthetic low molecular weight substrates. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1987 , 47, 405-10	2	12

3	The effect of catalase and methionine-S-oxide reductase on oxidised alpha 1-proteinase inhibitor. <i>Biological Chemistry Hoppe-Seyler</i> , 1986 , 367, 371-8		13
2	Cathepsin B-like cysteine proteinase activity in sputum and bronchoalveolar lavage samples: relationship to inflammatory cells and effects of corticosteroids and antibiotic treatment. <i>Clinical Science</i> , 1985 , 68, 469-74	6.5	33
1	Low molecular mass bronchial proteinase inhibitor and alpha 1-proteinase inhibitor in sputum and bronchoalveolar lavage. <i>Hoppe-Seyler's Zeitschrift Für Physiologische Chemie</i> , 1984 , 365, 587-95		26